GlassScriptPhysician profile
Isaac N Zedner
NPI 1871839233
$3,129.70
in general payments reported to CMS, 2019-2025
21 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $962 · 2022: $862 · 2023: $591 · 2024: $289 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,286.70 | 2021-2025 | Relistor, Trulance |
| Bioventus LLC | $552.30 | 2021-2023 | Supartz Fx Sodium Hyaluronate |
| Hikma Pharmaceuticals USA | $286.02 | 2021-2024 | Kloxxado |
| Collegium Pharmaceutical, INC. | $217.94 | 2021 | |
| Virtus Pharmaceuticals LLC | $217.36 | 2021-2025 | Levorphanol Tartrate |
| Forte Bio-Pharma LLC | $76.23 | 2023 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $67.47 | 2022-2024 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $56.38 | 2022-2023 | Seglentis |
| Depuy Synthes Sales INC. | $45.51 | 2021 | |
| Valinor Pharma, LLC | $43.03 | 2023 | Movantik |
| Si-Bone, INC. | $39.91 | 2021 | |
| Amgen INC. | $34.25 | 2021 | |
| Tonix Medicines, INC. | $32.16 | 2025 | Tonmya |
| Boston Scientific Corporation | $24.22 | 2022 | |
| Nevro Corp. | $23.41 | 2023 | Senza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $22.88 | 2025 | |
| Redhill Biopharma INC. | $22.32 | 2021 | |
| Abbott Laboratories | $22.27 | 2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $20.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Zedner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.